Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Blood

• Publication date

  2004-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD-2003-06-2122PMID 14551141
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clofarabine Is Active in Myelodysplastic Syndrome (MDS).

  2006cited by this paper
• Biochemical modulation of cytarabine triphosphate by clofarabine

  2005cited by this paper
• Recent advances in pediatric acute lymphoblastic and myeloid leukemia

  2003cited by this paper
• Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

  2003cited by this paper
• Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.

  2003cited by this paper
• What is the optimal therapy for childhood AML?

  2002cited by this paper
• SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia.

  2002cited by this paper
• Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats

  2002cited by this paper
• Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia.

  2002cited by this paper
• Purine and pyrimidine nucleoside analogs.

  2001cited by this paper
• Therapeutic options for acute myelogenous leukemia

  2001cited by this paper
• Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases.

  2001cited by this paper
• DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.

  2001cited by this paper
• High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells.

  2000cited by this paper
• Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995

  2000cited by this paper
• Med Pediatr Oncol

  1999cited by this paper
• Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2- fluoro-beta-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro- beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro- beta-D-ribofuranosyl)adenine in CEM cells.

  1999cited by this paper
• Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.

  1998cited by this paper
• Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia.

  1998cited by this paper
• Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response.

  1998cited by this paper
• Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.

  1996cited by this paper
• Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine.

  1996cited by this paper
• Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.

  1996cited by this paper
• Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells.

  1995cited by this paper
• Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia

  1994cited by this paper
• Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia.

  1994cited by this paper
• Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia.

  1994cited by this paper
• Fludarabine phosphate: a new active agent in hematologic malignancies.

  1994cited by this paper
• Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.

  1993cited by this paper
• 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.

  1992cited by this paper
• Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate.

  1991cited by this paper
• A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia.

  1991cited by this paper
• Cancer chemotherapy and biological response modifiers annual

  1987cited by this paper
• Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.

  1980cited by this paper

• Novel fused imidazotriazines acting as promising top. II inhibitors and apoptotic inducers with greater selectivity against head and neck tumors: Design, synthesis, and biological assessments.

  2023cites this paper
• Patient-Level Meta-analysis of Clofarabine in Acute Lymphoblastic Leukemia

  2023cites this paper
• Relaps/refrakter T hücreli akut lenfoblastik lösemili erişkin hastalarda klofarabin, siklofosfamid, etoposid (CLOVE): tek merkez deneyimi

  2023cites this paper
• Molecular and functional profiling of chemotolerant cells unveils nucleoside metabolism-dependent vulnerabilities in medulloblastoma

  2023cites this paper
• Clofarabine in Pediatric Acute Relapsed or Refractory Leukemia: Where Do We Stand on the Bridge to Hematopoietic Stem Cell Transplantation?

  2023cites this paper
• Carbohydrate-based drugs launched during 2000−2021

  2022cites this paper
• Quantification of clofarabine in urine and plasma by LC-MS/MS: suitable for PK study and TDM in pediatric patients with relapsed or refractory ALL

  2022cites this paper
• Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens

  2021cites this paper
• Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia

  2021cites this paper
• Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group.

  2021cites this paper
• Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial

  2021cites this paper
• Molecular interaction mechanism and performance evaluation in the liquid-liquid extraction process of ionic liquid-heptane-tertiary butanol based on molecular dynamics

  2021cites this paper
• Pediatric acute lymphoblastic leukemia

  2020cites this paper
• Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group

  2020cites this paper
• Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC

  2020cites this paper
• Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

  2020cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Pediatric Acute Lymphoblastic Leukemia, Version 2.2020

  2019cites this paper
• Relapsed Pediatric ALL

  2019cites this paper
• Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC

  2018cites this paper
• Clofarabine exerts antileukemic activity against cytarabine‐resistant B‐cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression

  2018cites this paper
• Transepithelial transport across the blood–testis barrier

  2018influential citation
• Clofarabine: a next-generation deoxyadenosine analogue

  2018cites this paper
• Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high‐risk stratum of patients with newly diagnosed high‐risk B‐lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131

  2018cites this paper
• Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study

  2018cites this paper
• 10 Pediatric Acute Myeloid Leukemia

  2018cites this paper
• Haploidentical Donor Transplantation Using a Novel Clofarabine-containing Conditioning Regimen for Very High-risk Hematologic Malignant Neoplasms

  2018cites this paper
• Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia

  2017cites this paper
• Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.

  2017influential citation
• Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in Pediatric Patients with Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia Consortium Study.

  2017cites this paper
• Preparative Regimen for Hematopoietic Stem Cell Transplantation (HSCT) in Pediatric Patients with Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia

  2017cites this paper
• Clofarabine: Structure, Mechanism of Action, and Clinical Pharmacology

  2017cites this paper
• Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience

  2017cites this paper
• Clinical Use of Clofarabine for Adults and Children with Leukemia

  2017cites this paper
• Relapsed Acute Lymphoblastic Leukemia of Childhood

  2017cites this paper
• Base-Modified Nucleosides as Chemotherapeutic Agents: Past and Future.

  2016cites this paper
• Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan

  2016cites this paper
• Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial Efficiency

  2016cites this paper
• Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?

  2016cites this paper
• Chemotherapeutic intervention by inhibiting DNA polymerases

  2016cites this paper
• Proscillaridin A effects on histone acetylation and C-MYC degradation in acute lymphoblastic leukemia

  2016cites this paper
• A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee)

  2016cites this paper
• Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults

  2016cites this paper
• Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide

  2016cites this paper
• Efficacy, safety and pharmacokinetics of clofarabine in Chinese pediatric patients with refractory or relapsed acute lymphoblastic leukemia: a phase II, multi-center study

  2016cites this paper
• Melatonin overcomes resistance to clofarabine in two leukemic cell lines by increased expression of deoxycytidine kinase.

  2015cites this paper
• Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.

  2015cites this paper
• Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant

  2015cites this paper
• Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study

  2015cites this paper
• How I treat Langerhans cell histiocytosis.

  2015cites this paper
• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

  2015cites this paper
• Nucleoside and HIV Drug Transport at the Blood-Testis Barrier

  2015cites this paper
• Hematopoietic stem cell transplantation following unsuccessful salvage treatment for relapsed acute lymphoblastic leukemia in children

  2015cites this paper
• Improving access to novel agents for childhood leukemia

  2015cites this paper
• Prognostic factors in adolescent and adult patients with acute lymphoblastic leukemia with two protocols of chemotherapy: a cross-sectional study.

  2015cites this paper
• Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia.

  2015cites this paper
• Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup

  2015cites this paper
• How I Treat How I treat Langerhans cell histiocytosis

  2015cites this paper
• Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents

  2015cites this paper
• A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD)

  2014cites this paper
• Clofarabine in the treatment of myelodysplastic syndromes

  2014cites this paper
• Severe Toxicity of Clofarabine combined to Cyclophosphamide and Etoposide in two Children with Relapsed Acute Lymphoblastic Leukaemia (ALL)

  2014cites this paper
• Severe Toxicity of Clofarabine combined to Cyclophosphamide and Etoposide in two Children with Relapsed Acute Lymphoblastic Leukaemia (ALL)

  2014cites this paper
• Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.

  2014cites this paper
• AAML0523: A report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia

  2014influential citation
• Overview of Therapy and Strategies for Optimizing Outcomes in De Novo Pediatric Acute Myeloid Leukemia

  2014cites this paper
• Phase II Trial of the Anti-CD 19 Bispecific T Cell – Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

  2014cites this paper
• Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant

  2014cites this paper
• Critical Illness as a Result of Anti- Neoplastic Therapy

  2014cites this paper
• Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia

  2014cites this paper
• Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia

  2014cites this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cites this paper
• Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

  2014cites this paper
• Acute Lymphoblastic Leukemia in Children

  2013cites this paper
• Phase I study of clofarabine in adult patients with acute myeloid leukemia in Japan.

  2013influential citation
• Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08‐09 trial

  2013cites this paper
• Advanced Targeted, Cell and Gene-Therapy Approaches for Pediatric Hematological Malignancies: Results and Future Perspectives

  2013influential citation
• Clofarabine salvage therapy for refractory high‐risk langerhans cell histiocytosis

  2013cites this paper
• myeloid leukemia (AML) in patients 50 years of age or older Clofarabine and cytarabine combination as induction therapy for acute

  2013cites this paper
• Older and new purine nucleoside analogs for patients with acute leukemias.

  2013cites this paper
• Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients

  2013cites this paper
• Targeting ribonucleotide reductase for cancer therapy

  2013cites this paper
• Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies.

  2013cites this paper
• Chemotherapy for Initial Induction Failures in Childhood Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study (POG 8764)

  2013cites this paper
• Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): A report from the Children's Oncology Group

  2013cites this paper
• Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approaches

  2013cites this paper
• Novel leukemic cell lines resistant to clofarabine by mechanisms of decreased active metabolite and increased antiapoptosis

  2013cites this paper
• cyclophosphamide for adults with refractory acute leukemias A phase 1 clinical-laboratory study of clofarabine followed by

  2013cites this paper
• Marketing Authorisations under Exceptional Circumstances for Oncology Drugs

  2013cites this paper
• Pediatric Relapsed or Refractory Leukemia: New Pharmacotherapeutic Developments and Future Directions

  2013cites this paper
• Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL

  2013cites this paper
• Relapsed and Refractory Pediatric Acute Myeloid Leukemia: Current and Emerging Treatments

  2013cites this paper
• Clofarabine in the treatment of elderly patients with acute myeloid leukemia.

  2013cites this paper
• Phase I dose‐escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias

  2012cites this paper
• How I treat relapsed childhood acute lymphoblastic leukemia.

  2012cites this paper
• Effective re-induction therapy with dasatinib and clofarabine in relapsed Philadelphia chromosome positive acute lymphoblastic leukemia

  2012cites this paper
• Institutional Experience With Clofarabine and Cytarabine in Relapsed Pediatric Acute Myeloid Leukemia

  2012cites this paper
• Novel and emerging drugs for acute lymphoblastic leukemia.

  2012cites this paper
• Clofarabine in Pediatric Patients with Refractory or Relapsed Leukemia: the GATLA experience.

  2012cites this paper
• Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients

  2012cites this paper
• A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia

  2012cites this paper